High content functional assays that can monitor parameters such as membrane integrity, cytokine release, and more, are critical to understanding target cell response to immunotherapies and allow for rational design of improved therapies.
This webinar will highlight:
- Challenges posed by current methods to screen the efficacy of immunotherapies
- The need for high content robust tools to evaluate current immunotherapeutic approaches such as adoptive cell therapy, checkpoint blockade etc.
The ability of the iQue Screener platform to acquire single-cell data on multiple biological readouts in a quantitative, high-throughput fashion and better understand functional efficacy of immuno-oncology therapies
Tom Duensing, PhD. CTO, IntelliCyt Corporation
Belen Ybarrondo, PhD. Adjunct Faculty, San Diego Community College